MedTrace Logo

Effects of Vitamin D in Parkinson's Disease (PD)

NCT01119131 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2016-03-07

Study results available
· View outcomes & findings →

Summary

A trial to measure the effects of vitamin D (versus a placebo) on balance, gait, falls, strength, and cognition in persons with Parkinson's disease.

Conditions

  • Parkinson Disease
  • Accidental Falls

Interventions

DRUG

Vitamin D3

Vitamin D3 at 10,000 IU a day

DIETARY_SUPPLEMENT

calcium

1000mg calcium daily

OTHER

Placebo

A placebo pill with similar appearance to the vitamin D3 will be given to those in the placebo arm

Sponsors & Collaborators

  • Oregon Health and Science University

    collaborator OTHER

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Amie Hiller, MD BS · VA Portland Health Care System, Portland, OR

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01119131 on ClinicalTrials.gov